Rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy.

ABSTRACT:

Background

Predictive biomarkers for anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) therapy are needed. Here, we validated the role of PD-1 single nucleotide polymorphisms (SNPs) in predicting the development of immune-related adverse events (irAEs) in patients with advanced cancer treated with anti-PD-1/PD-L1-based immunotherapy and defined the molecular mechanisms underlying the role of identified SNP candidate.

Methods

Blood samples, clinical-pathological characteristics, survival outcomes and irAEs were collected from two cohorts of patients: (1) patients with advanced cancer treated with anti-PD-1/PD-L1 alone and (2) patients with advanced non-small cell lung cancer (NSCLC) treated with anti-PD-1 in combination with platinum-based ch

SUBMITTER: Polcaro G 

PROVIDER: S-EPMC12684190 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature